From corporation-watch at countercorp.org Mon Jul 5 07:05:20 2010 From: corporation-watch at countercorp.org (Corporation Watch) Date: Mon, 5 Jul 2010 04:05:20 -0700 Subject: [Corp. Watch] Pfizer must still face lawsuits in 'Constant Gardner' case in Nigeria Message-ID: Top U.S. Court Rejects Pfizer Nigeria Lawsuit Appeal By James Vicini (Reuters, June 29) -- The U.S. Supreme Court declined to hear an appeal by Pfizer of a ruling by a lower court that reinstated lawsuits by Nigerian families who said the drugmaker tested an experimental antibiotic on their children without getting adequate consent. The justices, without comment, let stand a ruling by a U.S. appeals court in New York that allowed the lawsuits involving alleged harm caused by the drug, Trovan, to go forward. Pfizer conducted clinical trials of the drug in Nigeria during a 1996 meningitis epidemic. Families of some of the children who participated said the tests caused deaths and various injuries. According to the lawsuits, Pfizer violated international law by failing to obtain adequate consent from the patients. The lawsuits sought unspecified damages on behalf of the children who were part of the study. The drugmaker said the clinical study was conducted with the approval of the Nigerian government, and that it had the [verbal] consent of participants' parents or guardians. Pfizer said the trial violated no international or Nigerian laws. Pfizer said the appellate ruling expanded the jurisdiction of the U.S. Alien Tort Statute, a more than 200-year-old law, to American corporations doing business abroad, raising issues of national and international importance. A federal judge had initially dismissed the lawsuits, ruling the cases should be heard in Nigeria, not the United States. The appeals court reversed that decision. In 1998, the U.S. Food and Drug Administration approved Trovan for use by adults only. After reports of liver failure, its use in the United States was restricted to adult emergency care. The European Union banned its use in 1999. The Obama administration urged the justices to reject Pfizer's appeal, saying the questions presented did not warrant Supreme Court review. Pfizer said in a statement, "Today's decision, however, is not a determination on the merits of these cases, but rather a procedural ruling." It said the cases will go back to a federal judge in New York, where the company can again move to dismiss them on various grounds, including that Nigeria would be the appropriate place for the cases to be heard. "The company looks forward to presenting its defenses in court and remains confident it will ultimately prevail in these cases," Pfizer said. From corporation-watch at countercorp.org Mon Jul 5 21:27:55 2010 From: corporation-watch at countercorp.org (Corporation Watch) Date: Mon, 5 Jul 2010 18:27:55 -0700 Subject: [Corp. Watch] Apple is watching you - and the Germans are watching them Message-ID: Global Privacy Cop Germany to Investigate Apple's User Location Data By Dawn Kawamoto (Daily Finance, June 28) -- In its latest move to safeguard computer users' rights and burnish its reputation as a global privacy cop, Germany is seeking to dig deeper into Apple's collection of its customers' location-based data. Germany has been particularly busy of late amid the high-profile privacy debacles and debates surrounding tech titans from Google to Facebook. That should come as no surprise, given the country is considered the birthplace of data privacy. In 1970, the German state of Hesse passed a Data Protection Act, which marked the first data protection legislation in the world. "It was the first law on data protection, and traditionally a lot of regulation over privacy comes out of Germany," says Christopher Kuner, a partner at Hunton & Williams who heads up the law firm's international privacy and information management practice. "It's one of the most influential [countries on privacy policy] in Europe." The Hesse Act laid out the general framework for privacy laws of today, Kuner said, giving people the right to access their data and have control over it. Last week, computermaker Apple updated its privacy policy, notifying customers that it would collect, use, and sell their real-time geographic location information gathered when they're using Apple devices such as iPads and iPhones. Germany's justice minister was quoted in the widely read German magazine Der Spiegel calling on Apple to "open its databases to German data-protection authorities" to clarify the data it is collecting and how it will be used. Taking a Pro-Active, Pro-Consumer Approach German authorities also blew away Google's claims that its Street View cars were only gathering WiFi location-based data and no personal information. Google ate crow regarding its earlier statements about the Street View cars, acknowledging that it had discovered the snafu after German authorities asked to audit the WiFi data. Meanwhile amid concerns that social networking giant Facebook wasn't doing enough to safeguard its users' data, German Consumer Protection Minister Ilse Aigner earlier this month announced she would be deleting her Facebook account. She further noted that she believed her country's data-protection agency would likely hit Facebook with fines over its privacy settings, despite changes the company made to appease angry users. Those compromise moves have been largely panned worldwide. Each country in Europe has its own enforcement agencies to levy fines and take action in privacy matters, and the cases are usually handled by a data protection or consumer protection authority. Usually, those agencies are the ones with teeth, while ministry officials can initiate legislative or policy changes, Kuner noted. For companies doing business in Germany, the privacy bar is actually rising. Last year Germany's parliament, the Bundestag, increased regulations on the way both new and previously collected data can processed, and tightened restrictions on sharing information with third-party marketing partners. With this move against Apple, the German authorities are sending a clear signal that they aren't going to relax their vigilance. Internet companies with a global footprint would be wise to brush up on their German. From corporation-watch at countercorp.org Wed Jul 7 02:54:28 2010 From: corporation-watch at countercorp.org (Corporation Watch) Date: Tue, 6 Jul 2010 23:54:28 -0700 Subject: [Corp. Watch] U.S. companies would sooner dye than forego profits Message-ID: Group Urges Ban of 3 Common Dyes (CNN, June 30) -- The Center for Science in the Public Interest (CSPI) says food dyes pose a number of risks to the American public, and is calling on the Food and Drug Administration (FDA) to ban three of the most commonly used dyes: Red 40, Yellow 5, and Yellow 6. A new CSPI report says those dyes contain known carcinogens and contaminants that unnecessarily increase the risks of cancer, hyperactivity in children, and allergic reactions. "These synthetic chemicals do absolutely nothing to improve the nutritional quality or safety of foods, but can trigger behavior problems in children and, possibly, cancer in anybody," said CSPI executive director Michael Jacobson, co-author of the report. "The FDA should ban dyes, which would force industry to color foods with real food ingredients, not toxic petrochemicals," Jacobson said. The FDA has not read the report yet, an agency spokesperson said. "We appreciate the report from CSPI and look forward to reviewing it. We take our commitment to protecting children seriously". According to the report, tests done on lab animals raised health concerns about several of nine currently approved dyes. And every year, about 15 million pounds of these dyes wind up in our food, with a lot of them ending up in things like candy, fruit drinks, and cereals. The report is based on the FDA's own studies, and studies done by Industry and turned over to the FDA. But a statement from the Grocery Manufacturers Association (GMA), which represents the industry, says science shows food dyes are safe. "The safety of both artificial and natural colors has been affirmed through extensive review by the main global food safety bodies, including the FDA and the European Food Safety Authority," the GMA statement said. "Both the FDA and the food and beverage industry continually monitor any new research or data in this area to determine if a change in current policy is warranted," it added. "Food dyes are widely studied and the overwhelming majority of scientific evidence confirms the safety of artificial food colors." Britain's Food Standards Agency released research a few years ago that suggested a link between certain food coloring and hyperactivity in some children. Starting July 20th in the European Union, food containing some of these dyes will carry additional warning labels indicating possible adverse effects on "activity and attention in children." CSPI says there is more concern and more government oversight of dyes in Britain than in the U.S. For example, CSPI says, McDonald's Strawberry Sundaes sold in the UK get their color from fresh strawberries. The group says in the United States the color comes from Red dye 40. CSPI say in the UK, the orange coloring in Fanta soda comes from pumpkins and carrot extract. Here, it says the color comes from Red 40 and Yellow 6 dye. Rand Carpenter, a spokesperson for Coca-Cola, who makes Fanta, says they stand by their products in the United States ? and abroad. "Where colors are used in our products, they have been reviewed for safety by numerous health authorities and agencies, are permitted in every country where we operate, and are considered safe." From corporation-watch at countercorp.org Wed Jul 7 17:29:57 2010 From: corporation-watch at countercorp.org (Corporation Watch) Date: Wed, 7 Jul 2010 14:29:57 -0700 Subject: [Corp. Watch] For Big Pharma, lawsuit pay-outs just another budget item Message-ID: Merck Hit with $8 Million Verdict in Fosamax Trial By Linda A. Johnson (Associated Press, June 26) -- Drugmaker Merck said it will challenge its first loss in a trial blaming its osteoporosis drug for destroying a patient's jawbone after a federal jury on Friday awarded $8 million to the Florida woman. The U.S. District Court jury in New York awarded that amount in compensatory damages to Shirley Boles, 72, of Fort Walton, Fla., who alleged Merck's Fosamax destroyed her jawbone near her ears, causing serious pain and disability. "She feels vindicated, absolutely vindicated," said her attorney, Timothy O'Brien. The three-week trial ended after nearly four hours of deliberations Friday by a jury of three men and four women. It was the second for Boles, a retired sheriff's deputy in the sex crimes unit in Oskaloosa County, Fla. Her first trial ended last September in a mistrial. The jury concluded that Fosamax was "unreasonably dangerous due to defective design, and that its defective design was a legal cause of Mrs. Boles' injury." Merck attorney Paul Strain said Friday's verdict doesn't match the evidence, so Merck will challenge the decision. Strain plans to file a motion on July 16 asking U.S. District Judge John Keenan to either reverse the verdict, in Merck's favor, or set it aside and order a new trial. If that fails, Strain plans to appeal to the Second Circuit Court of Appeals in Manhattan. Boles took Fosamax for about 10 years, from 1997 through 2006, and suffered repeated jaw problems and complications after two tooth extractions in 2002. She was hospitalized for several days in 2004 to treat her condition. O'Brien said his client's decayed jaw bone drains through sores in her chin and she can only eat soft foods that don't require chewing. A doctor testified her condition has worsened, and the great-grandmother will need to have parts of her jawbone cut out and replaced with other bone, said O'Brien. O'Brien said his evidence showed that Fosamax provides no benefit in preventing bone fractures for women like Boles, who did not have osteoporosis. She had osteopenia, a condition in which bone density is beginning to decrease, and Fosamax is approved for preventing fractures in such women. Merck said the woman's dental problems were due to heavy smoking and periodontal disease. "We have many strong grounds" to challenge the verdict, Strain said. "The jury's verdict was a direct result of (O'Brien's) inflammatory and prejudicial remarks." Strain said the verdict was not what Merck had wanted, and that the company is "committed to fighting these cases." Merck, which has been paying out a $4.85 billion settlement to end roughly 50,000 lawsuits alleging its former painkiller Vioxx caused heart attacks and strokes, faces more than 1,400 lawsuits alleging Fosamax harmed patients. Two other Fosamax cases have come to trial. Strain said that in one, a jury voted in Merck's favor and in the other, a judge entered a summary judgment in Merck's favor. The next Fosamax trial is scheduled to begin on Nov. 1. Fosamax was once Merck's second best-selling drug, and the heavily advertised pill dominated the category of bone-preserving osteoporosis drugs until it got generic competition a few years ago. Fosamax had peak sales of $3.2 billion in 2005. From corporation-watch at countercorp.org Thu Jul 8 22:11:19 2010 From: corporation-watch at countercorp.org (Corporation Watch) Date: Thu, 8 Jul 2010 19:11:19 -0700 Subject: [Corp. Watch] EPA asks corporate foxes if public henhouses are safe Message-ID: EPA Accepts Industry Studies on Safety of Weedkiller in Drinking Water by Danielle Ivory (Huffington Post, July 8) -- Companies with a financial interest in a weedkiller that is sometimes found in drinking water paid for thousands of studies that federal regulators are using to assess the herbicide's health risks, records of the U.S. Environmental Protection Agency (EPA) show. Many of these industry-funded studies, which largely support atrazine's safety, have never been published or subjected to an independent, scientific peer-review. Meanwhile, some independent studies documenting potentially harmful effects on animals and humans are not included in the body of research the EPA deems relevant to its safety review, the Huffington Post has found. These studies include many that have been published in respected scientific journals. Even so, the EPA says that it would be "very difficult for someone to put a thumb on the scale" to slant the outcome. Atrazine is one of the most widely used herbicides in the U.S. An estimated 76 million pounds of the chemical are sprayed on corn and other fields in the U.S. each year, sometimes ending up in rivers, streams, and drinking water supplies. There is an intense scientific debate over its potential to cause cancer, birth defects, and hormonal and reproductive problems. As the Huffington Post reported in a series of articles last fall, the EPA failed to warn the public that the weedkiller had been found in drinking water in at least four states at levels above federal safety limits. Some water utilities are suing Syngenta, atrazine's manufacturer, to have it pay the costs of filtering the chemical. The EPA is now re-evaluating the health risks of atrazine, which was banned in the European Union in 2004 due to a lack of evidence to support its safe use. That ban includes Switzerland, where Syngenta is headquartered. The EPA expects to announce results of its re-examination of the herbicide in September 2010. It could take action ranging from restrictions on its use on crops to an outright ban. Or it could permit continued use without additional restrictions. The company, one of the world's largest agribusinesses, says the chemical has been used safely for decades and restrictions could prove devastating to farmers who are heavily dependent on the inexpensive herbicide. Atrazine poses "no harm" to the general population or to drinking water supplies, said company spokesman Steven Goldsmith. EPA records obtained by the Huffington Post show that at least half of the 6,611 studies the agency is reviewing to help make its decision were conducted by scientists and organizations with a financial stake in atrazine, including Syngenta or its affiliated companies and research contractors. More than 80 percent of studies on which the EPA are relying have never been published. This means that they have not undergone rigorous "peer review" by independent scientists, a customary method to ensure studies are credible and scientifically sound before they can be published in major journals. At the same time, several prominent studies by independent academic scientists in well-respected scientific journals -- showing negative reproductive effects of atrazine in animals and humans -- are absent from the EPA's list. That finding may raise concerns about how the agency is doing its work. Rep. Henry Waxman (D-Calif.), chairman of the House Energy and Commerce Committee, which oversees environmental regulators, told the Huffington Post that "it's critically important that EPA use all of the information at its disposal." Agency scientists may review studies not on the list, but EPA senior policy analyst William Jordan said that the 6,611 studies it is reviewing are those considered "relevant to the assessment of atrazine." 'Not Just Atrazine' EPA spokeswoman Betsaida Alcantara said the list was not exhaustive, and that some studies may not be on the list because they were not given an eight-digit "master record identification number," which the agency uses to keep track of studies. There is "no uniform practice" for assigning numbers to studies submitted by people other than those working for herbicide, fungicide, or pesticide manufacturers, she said. EPA officials said that with a limited budget, the agency must rely heavily on research sponsored by parties with a stake in the outcome. The agency's "test guidelines" governing how experiments are conducted -- the types and number of lab animals to be used, for instance -- provide sufficient safeguards against skewed results, officials said. "Companies have a very strong incentive to follow the guidelines," said EPA senior analyst Jordan. "We hope and think that we have written the guidelines with enough detail that it would be very difficult for someone to put a thumb on the scale, as it were -- to slant the outcome [or] to make something look safer than it is." Jennifer Sass, a senior scientist specializing in health issues at the Natural Resources Defense Council (NRDC), argues that relying on a company to test the safety of its own product -- an "inherent conflict" of interest -- is part of a larger pattern at the EPA. "It's not just happening with atrazine," she said. Hundreds of herbicides, pesticides, and other chemicals are regulated by the EPA, whose decisions can have significant implications for public health -- and on the abilities of an array of multinational companies to earn billions of dollars from sales in the U.S. Industry influence often is built into the regulatory process of the federal government. At the Food and Drug Administration, for instance, clinical trials conducted by pharmaceutical companies are used to determine whether pills and devices work and are safe. Makers of pesticides, herbicides, and fungicides must pay for studies of their products' safety. If the studies meet agency rules for conducting the tests, by law the EPA must accept them. The 'Funding Effect' But is industry-funded research always reliable? A pair of scientists funded by the National Science Foundation, the U.S. Department of Agriculture, and the EPA scrutinized a 2008 Syngenta-funded Canadian study that is not on the EPA's list. The widely cited study focused on the herbicide's effects on fish and other aquatic creatures. University of South Florida biologists Jason Rohr and Krista McCoy said they found 122 inaccurate and 22 misleading statements in the study, of which 96.5 percent appeared to support atrazine's safety. They published their critique in the March 2010 issue of the journal Conservation Letters. Rohr and McCoy also asserted that the 2008 study misrepresented results, figures, and conclusions of more than 50 other studies. For example, it incorrectly suggested that only one scientist had demonstrated the chemical's gender-altering effects on frogs. In fact, several other scientists demonstrated such effects. The study also dismissed one of Rohr's papers as invalid, wrongly claiming that the researcher had filtered atrazine out of a water tank while trying to assess the chemical's effect on the aquatic organisms in the tank. Rohr, who served on an EPA advisory panel examining atrazine last year, told the Huffington Post that he felt compelled "to set the record straight given the potential policy and environmental implications of these misconceptions and inaccuracies." The author of the Canadian study, University of Guelph (Ontario) biologist Keith Solomon, declined to respond to questions about his financial ties to Syngenta, the company's influence, or the inaccuracies and mischaracterizations that the South Florida biologists said they had uncovered. Solomon noted that other scientists had come to similar conclusions, and that governments in the U.S. and Australia had not found any significant risk to creatures living in water. Several of Solomon's studies are on the EPA's list. Wendy Wagner, an expert in environmental policy at the University of Texas law school, said that the criticism of the Canadian study demonstrates a phenomenon sometimes referred to as "the funding effect." "It is next to impossible to squeeze all of the discretion out of a researcher, and when he has a strong incentive to find a particular result, the result can be unreliable and badly biased research," said Wagner, an authority on the influence of politics and special interests on science. "There is compelling evidence that bias still pervades sponsored pesticide research -- [including] research that presumably is done in accord with EPA's guidelines," Wagner said. Meanwhile, some independently-funded academic research published in major scientific journals is not on the list of papers the EPA is using to make its decisions on atrazine -- including studies published in the Proceedings of the National Academy of Sciences, Environmental Health Perspectives, and Nature. Many works by independent academic scientists such as Tyrone Hayes and Rohr, who have demonstrated a range of potential reproductive and hormonal effects of the chemical, are not on the list. EPA officials said they were not able to provide a list of all omitted research. Some peer-reviewed studies from prestigious journals fail to meet the agency's standards, said EPA analyst Jordan, citing as an example work by scientists such as Hayes, who recently found that low doses of atrazine could turn male frogs into female frogs. Jordan explained that the agency couldn't rely on Hayes' and the other scientists' research in part because the government lacked protocols for testing chemicals on frogs. So the EPA developed those guidelines and asked Syngenta to study the issue. The company's researchers reported that they were unable to replicate Hayes' findings. Jordan said the Syngenta study "superseded" Hayes' and the other scientists' studies. The EPA's website currently states that atrazine causes no such adverse effects on frogs and that "no additional testing is warranted" to address the issue. Environmental groups have criticized the EPA for allowing chemical companies to wield disproportionate influence over regulatory decisions. While evaluating the safety of atrazine in 2003, the EPA allowed Syngenta representatives to participate in closed-door negotiations with the agency, according to documents obtained by the NRDC in 2004. Missing Evidence EPA spokesman Dale Kemery defended the practice of omitting some studies. The agency's safety "review may not include every study that has been conducted, since some may not meet the standards that are appropriate for a regulatory setting, or they may not be on target for the issues to be assessed." The EPA considers industry-sponsored studies "scientifically more robust than studies generated by people in academia," said Jordan, the agency's senior policy analyst. "That's generally because companies spend more money on their studies, and can attend to details that are potentially important that people in academia just can't afford to do." Agency oversight of the thousands of unpublished studies on the list is just as rigorous as peer review by scientists prior to publication in a scientific journal, Jordan added. "I know people might not agree with this proposition, but I believe that EPA scientists constitute a peer-review," he said. "We go over the studies with a fine tooth comb." A spokeswoman for CropLife America, the Washington D.C.-based trade association that represents pesticide and herbicide manufacturers, said EPA oversight is thorough, regardless of whether studies have appeared in peer-reviewed journals. "Whether or not they have been published, the studies submitted to EPA in support of pesticide product registrations are subject to scientific review by EPA scientists that is equally, if not more, rigorous and demanding than the pre-publication peer review conducted by any scientific journal," said spokeswoman Mary Emma Young. But some people are skeptical about the rigor of the EPA's scrutiny. "What worries me," said the University of Texas' Wagner, "is the possibility that there isn't time or energy within EPA to give a lot of oversight to this unpublished, industry-funded research, especially when the number of unpublished studies for a chemical like atrazine are in the thousands." Epidemiologist Lynn Goldman said it is normal and necessary for the agency to accept unpublished and industry-funded studies, most of which would not be interesting enough to publish in scientific journals. "This is the way that the system was built by Congress. It could be changed, but the EPA does not have the authority to turn the system upside down" by itself, said Goldman, a former assistant EPA administrator for toxic substances during the Clinton administration. The existence of a list of relevant research for EPA review has played a prominent role in public arguments in favor of the herbicide's safety. Journalists, scientists, and advocates for atrazine have frequently cited the "6,000" studies of atrazine that have been conducted. "Atrazine is one of the most well-examined pesticides in the marketplace," said Anne Lindsay, then a senior official in the EPA's Office of Pesticide Programs, during Congressional testimony in 2005. "There are nearly 6,000 studies in EPA files on the human health and environmental effect of atrazine." Syngenta now cites the number in its press materials and on its website -- not merely as a tally of studies, but as proof of its safety. "Atrazine passes the most stringent, up-to-date safety requirements in the world," said spokesman Paul Minehart. "In 2006, the U.S. Environmental Protection Agency re-registered atrazine based on the overwhelming evidence of safety from nearly 6,000 studies."